Bone mineral density, kidney function and participant‐reported outcome measures in women who switch from tenofovir disoproxil emtricitabine and a nonnucleoside reverse transcriptase inhibitor to abacavir, lamivudine and dolutegravir - Laura Waters, Lucy Campbell, Fowzia Ibrahim, Birgit Barbini, Amanda Samarawickrama, Frank A. Post, Chloe Orkin, Oluwayomi Adegbaju, Lisa Hamzah, Priya Bhagwandin, Julie Fox, Ana Canoso, Stephen Kegg, Tarik Moussaoui, Julianne Lwanga - Dissemin

Language
Login

Published in

Wiley, HIV Medicine, 4(23), p. 362-370, 2021

DOI: 10.1111/hiv.13215

Links

ORCID
Wiley | PDF

Tools

Export citation

Search in Google Scholar

Bone mineral density, kidney function and participant‐reported outcome measures in women who switch from tenofovir disoproxil emtricitabine and a nonnucleoside reverse transcriptase inhibitor to abacavir, lamivudine and dolutegravir

Journal article published in 2022 by Laura Waters, Lucy Campbell, Fowzia Ibrahim, Birgit Barbini, Amanda Samarawickrama, Frank A. Post, Chloe Orkin, Oluwayomi Adegbaju, Lisa Hamzah, Priya Bhagwandin, Julie Fox, Ana Canoso, Stephen Kegg, Tarik Moussaoui, Julianne Lwanga and other authors.

This paper is made freely available by the publisher.

This paper is made freely available by the publisher.

Full text: Download

Green circle

Preprint: archiving allowed

Upload

Orange circle

Postprint: archiving restricted

Upload

Red circle

Published version: archiving forbidden

Policy details

Data provided by

SHERPA/RoMEO